Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
US12240904B2 · kind B2 · utility
0Cited by
3References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 5, 2019 |
| Grant date | Mar 4, 2025 |
| Priority date | — |
| Expiry date | Jun 27, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.